BBIO Q2 2024 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+32.1% YoY

Gross Profit

$2M72.4% margin

Operating Income

-$176M-8096.8% margin

Net Income

-$73M-3388.2% margin

EPS (Diluted)

$-0.39

QoQ Revenue Growth

-99.0%

Cash Flow

Operating Cash Flow

$75M

Free Cash Flow

$72M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$794M

Total Liabilities

$1.9B

Stockholders' Equity

-$1.1B

Cash & Equivalents

$547M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	+32.1%
Gross Profit	$2M	$1M	+50.7%
Operating Income	-$176M	-$146M	-20.2%
Net Income	-$73M	-$158M	+53.5%